KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Issued (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Shares Issued for 15 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 24.43% to $8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.6 million through Dec 2025, up 152.32% year-over-year, with the annual reading at $37.6 million for FY2025, 152.32% up from the prior year.
  • Shares Issued for Q4 2025 was $8.6 million at Supernus Pharmaceuticals, down from $23.7 million in the prior quarter.
  • The five-year high for Shares Issued was $23.7 million in Q3 2025, with the low at $524000.0 in Q3 2021.
  • Average Shares Issued over 5 years is $3.9 million, with a median of $2.4 million recorded in 2022.
  • The sharpest move saw Shares Issued surged 6921.88% in 2021, then crashed 88.54% in 2023.
  • Over 5 years, Shares Issued stood at $1.6 million in 2021, then soared by 79.62% to $2.8 million in 2022, then plummeted by 61.4% to $1.1 million in 2023, then soared by 529.76% to $6.9 million in 2024, then rose by 24.43% to $8.6 million in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $8.6 million, $23.7 million, and $3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.